To evaluate the effectiveness of topiramate monotherapy or add-on therapy in patients with juvenile myoclonic epilepsy

Objective/methods: Open-label study enrolling patients age 12–65 years with a confirmed diagnosis of uvenile myoclonic epilepsy (JME) (myoclonic jerks and PGTCS or an EEG with generalized epileptiform abnormalities consistent with a clinical diagnosis of JME), age of disease onset between 8–26 years. Patients had to have myoclonus and/or >1 PGTCS within the 3-month retrospective baseline. Eligible patients were randomized (2:1) to 26 weeks treatment with topiramate monotherapy (TPM) (target, 3–4mg/kg/day; maximum, 9mg/kg/day) or VPA (target, 10mg/kg/day; maximum, 60mg/kg/day or 750mg/day if >16 years of age). 12…